Alex Mogle
Direktor/Vorstandsmitglied bei MAPI PHARMA LTD
Profil
Alex Mogle is currently a Director at Pharma Two B Ltd.
and a Director & Vice President-Corporate Development at Mapi-Pharma Ltd.
He was previously a Vice President-Strategy at Stem Cell Medicine Ltd.
Mr. Mogle received an undergraduate degree and an MBA from The Hebrew University of Jerusalem.
Aktive Positionen von Alex Mogle
| Unternehmen | Position | Beginn |
|---|---|---|
| MAPI PHARMA LTD | Direktor/Vorstandsmitglied | 01.06.2012 |
Pharma Two B Ltd.
 Pharma Two B Ltd. Pharmaceuticals: GenericHealth Technology Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Alex Mogle
| Unternehmen | Position | Ende |
|---|---|---|
Stem Cell Medicine Ltd.
 Stem Cell Medicine Ltd. Pharmaceuticals: OtherHealth Technology Stemcell Medicine Ltd. develops and commercializes cellular therapies. It develops products from a number of tissue sources, such as adipose tissue stem cells for ischemic indications and from T cells for solid tumor-directed immunotherapies. The company was founded by Ehud Marom in 2010 and is headquartered in Jerusalem, IL. | Corporate Officer/Principal | - |
Ausbildung von Alex Mogle
| The Hebrew University of Jerusalem | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Mapi-Pharma Ltd.
 Mapi-Pharma Ltd. Pharmaceuticals: MajorHealth Technology Mapi-Pharma Ltd. is a clinical stage pharmaceutical company engaging in the development of extended-release versions of existing commercial generic drugs. Its products include injections for treatment of multiple sclerosis, active pharmaceutical ingredient, and oral drugs for the treatment of neuropathic pain. The company was founded by Ehud Marom in 2008 and is headquartered in Ness Ziona, Israel. | Health Technology |
Stem Cell Medicine Ltd.
Stem Cell Medicine Ltd. Pharmaceuticals: OtherHealth Technology Stemcell Medicine Ltd. develops and commercializes cellular therapies. It develops products from a number of tissue sources, such as adipose tissue stem cells for ischemic indications and from T cells for solid tumor-directed immunotherapies. The company was founded by Ehud Marom in 2010 and is headquartered in Jerusalem, IL. | Health Technology |
Pharma Two B Ltd.
Pharma Two B Ltd. Pharmaceuticals: GenericHealth Technology Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel. | Health Technology |
